{
  "response": {
    "text": "The clinical trial NCT02838420 (ALESIA) compared alectinib and crizotinib as first-line treatments for ALK-positive non-small-cell lung cancer in Asian patients. The study found that alectinib was more effective than crizotinib.\n\nBased on the study results, the less effective regimen ingredient in this trial was crizotinib.\n\nINGREDIENT: CRIZOTINIB",
    "citations": []
  }
}